We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Transcranial Magnetic Stimulation and Anti-epileptic Effect: Optimization and Evaluation With Electrophysiology.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00382707
Recruitment Status : Completed
First Posted : September 29, 2006
Last Update Posted : August 30, 2011
Sponsor:
Information provided by:

Study Description
Brief Summary:
Epileptic disease is characterised by enhanced brain excitability. Low frequency repetitive transcranial magnetic stimulation (rTMS) can be an effective treatment for refractory frontal epilepsy. Thought, physiological mechanisms of its effectivity are still unknown. It is yet possible to evaluate cortical excitability and inhibition with TMS-coupled electromyography before and after rTMS sessions ; this could provide clues for basic mechanisms of rTMS effects on the epileptic brain. We assume that rTMS decrease brain excitability by improving brain inhibition. Such an information could help for treating patients with both pharmacological and non-pharmacological methods.

Condition or disease Intervention/treatment
Refractory Frontal Lobe Epilepsy Device: cortical magnetic stimulation provided by an eight-shaped coïl placed upon the skull.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Transcranial Magnetic Stimulation and Anti-epileptic Effect: Optimization and Evaluation With Electrophysiology.
Study Start Date : May 2006
Study Completion Date : August 2011


Arms and Interventions


Outcome Measures

Primary Outcome Measures :
  1. Electrophysiological parameters for cortical excitability measured just before and after rTMS, 4 hours later and 24 hours later.

Secondary Outcome Measures :
  1. Clinical efficacity on seizure intensity and frequency.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Cryptogenic frontal lobe epilepsy
  • Normal cerebral MRI
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00382707


Locations
France
Département de Neurologie - Hôpital Civil
Strasbourg, France, 67091
Institut de Physique Biologique
Strasbourg, France, 67091
Sponsors and Collaborators
University Hospital, Strasbourg, France
Investigators
Study Director: Serge CHASSAGNON, MD Hôpitaux Universitaires de Strasbourg
More Information

ClinicalTrials.gov Identifier: NCT00382707     History of Changes
Other Study ID Numbers: 3540
First Posted: September 29, 2006    Key Record Dates
Last Update Posted: August 30, 2011
Last Verified: August 2011

Keywords provided by University Hospital, Strasbourg, France:
repetitive transcranial magnetic stimulation
low frequency
frontal lobe epilepsy
brain excitability
electromyography

Additional relevant MeSH terms:
Epilepsy
Epilepsy, Frontal Lobe
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Epilepsies, Partial
Anticonvulsants